Compositions of matter and methods of treating cancer patients may prevent or limit cardiotoxicity during or after chemotherapy, and/or may prevent or lower resistance to anthracycline drugs, both of which are believed to be caused by the human enzyme carbonyl reductase. Thus, the compositions and methods may be used to reduce the dosages of anthracycline anti-cancer drugs necessary to produce a desired cancer-cell-killing performance. Preferred embodiments comprise treating cancer patients with...

Compositions of matter and methods of treating cancer patients may prevent or limit cardiotoxicity during or after chemotherapy, and/or may prevent or lower resistance to anthracycline drugs, both of which are believed to be caused by the human enzyme carbonyl reductase. Thus, the compositions and methods may be used to reduce the dosages of anthracycline anti-cancer drugs necessary to produce a desired cancer-cell-killing performance. Preferred embodiments comprise treating cancer patients with...

A pharmaceutical composition containing hexachlorophene having anticancer activity is provided to inhibit growth of cancer cells by inhibiting Wnt/beta-catenin response transcription without toxicity, so that the composition selectively treats colon cancer and malignant melanoma. The pharmaceutical composition for treating cancer contains hexachlorophene, its derivatives or pharmaceutically acceptable salts thereof, wherein the cancer is colon cancer or malignant melanoma

FIELD: medicine, pharmacy. SUBSTANCE: antiseptic agent can be taken among compounds evolving oxygen and halogen, metal compounds, for example, silver and mercury compounds, organic disinfecting substance including among them compounds evolving formaldehyde, alcohols, phenols including alkyl- and aryl-phenols and also halogenated phenols, quinolines and acridines, hexahydropyrimidines, quaternary ammonium compounds and iminium salts and guanidines. Antiseptic is taken among the group consisting o...

Absorbent articles containing an additive are disclosed. The absorbent articles include an effective amount of an inhibitory compound such as cerulenin, triclosan, or hexachlorophene, for example, to substantially inhibit the production of TSST-1 by Gram positive bacteria.